
Cobio Diagnostics: Pioneering biotech firm specializing in bacterial identification and antibiotic resistance testing.
Cobio Diagnostics, founded in 2016 and based in Golden, Colorado, is a biotechnology company dedicated to developing advanced diagnostics for bacterial identification and phenotypic antibiotic resistance testing. The company's core mission is to combat the growing threat of antibiotic resistance, which poses significant risks to global health, food security, and development. Cobio Diagnostics offers innovative diagnostic solutions aimed at accurately identifying bacterial infections and determining their resistance profiles, thereby enabling more effective treatment strategies.
Notable figures affiliated with Cobio Diagnostics include experts in biotechnology and healthcare, although specific names are not provided. The company has attracted attention from investors interested in addressing critical public health challenges. Key achievements include the development of cutting-edge diagnostic tools that have the potential to significantly reduce the incidence of antibiotic-resistant infections. Cobio Diagnostics' impact lies in its contribution to improving patient outcomes and supporting global efforts to manage antibiotic resistance.
Cobio Diagnostics' most recent funding round was for $984k (USD) in August 2024.
As of Aug 20, 2024, Cobio Diagnostics has disclosed funding of $3.7M (USD).

BioAmp diagnostics
bioampdx.com

FYR Diagnostics
fyrdiagnostics.com

3i Diagnostics
3idx.com

Day Zero Diagnostics

MicrobeDx
microbedx.com
Global BioDiagnostics

Gemelli Biotech
gemellibiotech.com
Microbial Pulse Diagnostics

ID Genomics
idgenomics.com

GeneCapture
genecapture.com

DxDiscovery
dxdiscovery.com

CoWin Biosciences
cwbiosciences.com

Astek Diagnostics
astekdx.com

Accelevir Diagnostics

Accelerate Diagnostics

Gamma Diagnostics

Prompt Diagnostics
prompt-dx.com

PhageTech
phagetech.com

Pediatric Bioscience

First Light Diagnostics
firstlightbio.com